












with health claims would provide well-documented
alternatives for increasingly health-conscious
consumers, for the benefit of consumer health.
Furthermore, possibilities to develop and market such
foods have the potential to focus on and promote
nutrition as a main quality parameter with resulting
improvements of the nutritional composition of a
broader range of food products for the benefit of
consumers in general. 
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CHRONIC DISEASE PREVENTION
Global strategies to prevent chronic
diseases1
Department of Chronic Diseases and Health Promotion, Noncommunicable Diseases and
Mental Health, World Health Organization, Geneva, Switzerland
Robert Beaglehole
Chronic, non-communicable diseases such as heart
disease, stroke, cancer and diabetes, despite being the
leading global causes of death and disability, are
notably absent from international development
discussions and actions.  This paper makes four points.
First it reaffirms the critical importance of chronic
diseases as causes of ill health globally – and especially
in low- and middle-income countries – and their
potential, and underappreciated, constraint on
economic and social development in all countries.
Secondly, it emphasises the unrealised potential for the
prevention and control of all major chronic diseases.
Thirdly, it considers the absence of chronic diseases
from the Millennium Development Goals (MDGs) and
how best to align the chronic disease agenda with the
MDG agenda. Fourthly, it highlights the importance of
operational research to support the implementation of
global strategies for the prevention and control of
chronic diseases, rather than more epidemiological,
clinical or laboratory research.
Since the early decades of the last century chronic
diseases have been the leading causes of death and
disease in most wealthy countries.  Only recently has it
been appreciated that these diseases are now the
leading cause of death in all regions of the world,
except Africa.
This year there will be an estimated 58 million deaths,
35 million of which will be due to chronic diseases.
Approximately 16 million of these chronic disease
deaths will be premature, i.e. occurring under the age
of 70 years.  Of all chronic disease deaths 80% occur in
low- and middle-income countries, and the death rates
in these countries are considerably higher than in high-
income countries.  The burden of chronic diseases (as
measured by disability adjusted life-years) is
increasing, now accounting for nearly half of the global
burden of disease (all ages).  While the proportion of
The burden of chronic diseases
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burden from chronic diseases in adults in developed
countries remains stable at over 80%, the proportion in
middle-income countries has already exceeded 70%.
Surprisingly, almost 50% of the adult disease burden in
the high-mortality regions of the world is now
attributable to chronic diseases.2 Population ageing,
urbanisation and changes in the population distribution
of risk factors, in response to local and global forces,
have accelerated the epidemic of chronic diseases in
low- and middle-income countries.3
Cardiovascular diseases will account for approximately
16 million deaths in 2005 and for 13% of the disease
burden among adults over 15 years of age. Coronary
heart disease and cerebrovascular disease (stroke) are
the two leading causes of mortality and disease burden
among adults over age 60.  An estimated 7.5 million
cancer deaths will occur this year. Lung cancer is the
most readily preventable cancer with an estimated 1.5
million deaths reflecting the emergence of the tobacco
epidemic in low-income and middle-income countries.
Although we are most comfortable with epidemiological
expressions of the burden of chronic diseases, from a
policy perspective the social and economic burdens are
at least of equal importance.  Unfortunately, and in
contrast to considerable work on the impacts of
infectious diseases – for example, by the Commission
on Macroeconomics and Health4 – there have been few
systematic studies of these impacts of chronic
diseases. The recent Macroeconomics and Health
Report for Central and Eastern Europe highlights the
importance for this region of reducing adult mortality,
with the expected gains being much greater than for
reductions in childhood mortality.5
The impact of chronic diseases on social institutions
will, fortunately, never be as acute as HIV/AIDS; it will
be less visible, but in the long term they will have
enormous adverse effects on societies.  There is
considerable evidence from wealthy countries of the
costs of specific chronic conditions – diabetes,6
cardiovascular diseases7 and, increasingly, obesity,8 for
example, have received much attention.  Recent, albeit
limited, data from five low- and middle-income
countries highlight the impact of cardiovascular
disease on the middle-aged workforce, just as was
apparent in wealthy countries when these epidemics
were at their peak in the middle decades of last
century; this report also stresses the equal importance
of cardiovascular disease to women and men.9 The
forthcoming World Health Organization report,
Preventing Chronic Diseases: A Vital Investment, will
present estimates of the economic impact of heart
disease, stroke and diabetes on the economies of
several countries.10
An impressive body of research has identified the
causes of the major chronic disease epidemics, with
the notable exception of breast and prostate cancers.
The current distribution of the major risk factors for
chronic diseases are indicators of future health status,
and 5 of the top 10 risks worldwide are specific to
chronic diseases.11 These major chronic disease risk
factors – tobacco use, inappropriate diet and physical
inactivity (primarily expressed through unfavourable
lipid concentrations, high body mass index, and raised
blood pressure) – explain at least 75 - 85% of new cases
of coronary heart disease.12 In the absence of elevations
of these risk factors, coronary heart disease is a rare
cause of death, at least until the very oldest age groups.
Unfortunately, the vast majority of the populations in
almost all countries are at risk of developing chronic
diseases because of higher than optimal levels of the
main risk factors.  Only about 5% of adult men and
women in wealthy countries are at low risk with
optimal risk factor levels.  There are only a few very
poor countries in which these factors have not yet
emerged as major public health problems.
It is not surprising, given the extensive knowledge on
the causes of chronic diseases, that they are on the
whole preventable.  Application of this knowledge has
had a major beneficial impact on chronic disease death
rates in many wealthy countries, especially for
cardiovascular disease and, to a lesser extent, lung
cancer in men.13 These declines account for the rapid
increases in life expectancies in adults in many wealthy
countries, even though much of this benefit has
accrued to the more advantaged segments of these
populations.
The absence of chronic diseases from the MDGs is
notable, given their domination of the global mortality
and burden of disease patterns in all regions except
Africa, and their contribution to health inequalities.
The origin of the MDGs in the international
development discourse in the 1990s helps explain this
absence. The United Nations conferences in the 1990s
focused on a narrow range of health concerns around
maternal and child health issues and infectious
diseases, and came up with a set of targets that
concentrated attention on these issues. There is a need
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and control targets and at the same time work towards
broadening the health development agenda in line with
the complexities of the health situation in all countries. 
There are several reasons to attempt to align the
chronic disease agenda with the MDGs. First, the
MDGs represent a compact between rich and poor
countries and this key concept of partnership can be
used to further the chronic disease prevention and
control agenda, especially given the emerging evidence
on the economic implications of chronic diseases,
which are probably of equal importance to other causes
of ill health in perpetuating poverty.  Secondly, there is
a real danger that an overriding commitment to the
MDG agenda will distort resource allocations for
countries, donors and the WHO, away from the social
and economic reality.  As poor countries build their
health systems to provide prevention and control
services to achieve key MDG goals, these same
services could readily be used for chronic disease
prevention and control programmes.  Finally,
monitoring of MDG 6 will in future include trends in
health-adjusted life expectancy (HALE). Since chronic
diseases are major contributors to HALE, their
relevance to the MDGs is reinforced.
The reasons for the neglect of chronic diseases by
international development agencies are complex.  In all
countries there is the inevitable priority given by health
systems to acute infections, especially those like severe
acute respiratory syndrome (SARS), which can have
major and rapid adverse economic impacts.  There is a
misconception that chronic diseases are still the
preserve of men in wealthy countries, despite the
irrefutable evidence to the contrary.  The notion that
these conditions are caused by ‘lifestyles’ totally under
the control of individuals not only persists in most
countries but in some is the dominant paradigm for
health, despite the overwhelming importance of the
social, economic and cultural environment in
determining human behaviours. Since the major
determinants of chronic diseases are not under the
direct control of individuals, the case for government
leadership in the chronic disease agenda is strong. 
Essentially, the causes of chronic diseases are known
and there is little need for research to identify new and
unknown causes.  However, further research is required
to explore the many variations in the occurrence of
chronic diseases, both within and especially among
countries.14 Of particular interest is life course research
examining influences that accumulate over a lifetime,
and complementary attempts to explain socioeconomic
inequalities in risk, between both individuals and
regions. 
A critical research issue is the need for a
comprehensive analysis of the non-health effects of
chronic diseases.  Cost-of-illness studies are only a
start.  More important is further assessment of the
direct and indirect economic effects of chronic diseases
on societies, communities and families and on already
stretched health services. These impacts will only
increase as societies age. 
A major priority for new research is prevention policy
and programme effectiveness and issues of importance
for the spread of the chronic disease epidemics to poor
populations.  Policy-directed research will have the
biggest public health payoff in the short term, as it has
had for tobacco control.  There is an urgent need for
epidemiologists and other public health scientists to
explore the applicability of new research methods to
the underlying social, economic and cultural
determinants of chronic diseases.  Some of the required
research is more a matter of academic interest; some
may in time provide extra leads to effective public
health action.  However, the unresolved issues should
not detract from the urgency of applying what we
know, especially in low- and middle-income countries
that will bear the brunt of the global chronic disease
epidemics. 
The main issue for policy makers, at all levels of public
health in low- and middle-income countries, is how to
deal with the growing burden of chronic diseases in the
presence of persisting communicable disease
epidemics.  Furthermore, this challenge must be faced
even where health system resources are already
inadequate.  Although considerable policy gains can be
made very cheaply, especially inter-sectorally, extra
resources must be found, just as for infectious disease
prevention and control. This requires a greater share of
national resources for health care, better use of existing
resources, and new sources of funding.  A special tax
on tobacco products for disease prevention and control
programmes is a readily available source of new funds,
and experience with these forms of funding is growing.
Another critical policy issue concerns the appropriate
balance between primary and secondary prevention
and between the population and high-risk approaches
to primary prevention.  If the goal is to increase the
proportion of the population at low risk and to ensure
that all groups benefit, the strategy with the greatest
potential is the one directed at the whole population,
not just people with high levels of risk factors or
established disease.15 All other strategies will, at best,
only blunt the epidemics and probably increase
inequalities; they will not prevent the epidemics.  The
ultimate public health policy goal is the reduction of
population risk, and since most of the population in
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that the majority of prevention and control resources
should be directed towards this goal in the entire
population.  Evidence is available in support of the
cost-effective policies required for the task of making
the small – but powerful and surprisingly rapid – shifts
in risk distributions in entire populations in a
favourable direction.9 Similarly, management decisions
based on measures of overall risk are more cost-
effective than those based on single risk factors. 
Untold lives are lost unnecessarily because of
inadequate acute and long-term management of
chronic diseases.  Relatively cheap interventions for
chronic diseases are available,16 and single combination
pills including aspirin and drugs for blood pressure and
cholesterol lowering for possible use in chronic care are
under development.17 Even in wealthy countries,
however, the potential of these and other interventions
for secondary prevention is far from fully utilised.  The
situation in poorer countries is even less satisfactory.
There are many opportunities for co-ordinated chronic
disease risk reduction, care and long-term manage-
ment.  Smoking cessation and the identification and
management of diabetes, for example, are just two
priorities.  Cost-effective interventions, such as the use
of aspirin in people with myocardial infarction, would
prevent a quarter of the deaths associated with heart
attacks and are usually much more cost-effective than
more radical interventions.
A coherent policy framework, encompassing legislation,
regulation and mass education, is critical for chronic
disease prevention and control, since individual
behaviour change is difficult in the absence of
conducive environmental alterations.  A suggested
stepwise framework for a comprehensive response to
chronic disease prevention and control is under
development and can be modified according to national
needs, goals and targets.10
Unfortunately, the global and national capacity to
respond to chronic disease epidemics is woefully
inadequate.  Few countries have implemented
comprehensive prevention and control policies and
development of capacity, especially for policy and
programme development and implementation research,
has not kept pace with the epidemiological transition.
The gaps between the needs for chronic disease
prevention and control and the capacity to meet them
will grow even wider unless urgent steps are taken.
The WHO and governments cannot confront the
challenges of chronic disease prevention and control
alone.  The WHO Global Strategy on Diet, Physical
Activity and Health is the strategic framework within
which the WHO and Member States can work together
across sectors in preventing chronic diseases.  This
population-wide prevention strategy is based on
extensive consultations with stakeholders: Member
States, the United Nations and intergovernmental
organisations, civil society and the private sector.
Globally, there is still only limited advocacy for the
prevention and control agenda and what there is tends
to be fragmented.  The lack of unified advocacy for
health promotion compares poorly with the growing
dominance of commercial and consumer groups that
have placed treatment at the centre of health policy
debates and funding priorities. Broader alliances of
major health professional bodies, NGOs, consumer
groups and others are needed to promote the
prevention of major risk factors for chronic diseases and
to track progress to agreed national and global goals –
perhaps modelled on the MDGs.  Since the
determinants of chronic diseases are multisectoral,
advocacy and action must extend well beyond the
health sector.  The involvement of NGOs in articulating
the demand for speedy implementation of policies and
programmes relevant to chronic disease control is
critical for catalysing policy change and for mobilising
communities to ensure that the benefits flow to the
entire population. 
While the pace of globalisation of the major risks for
chronic diseases is increasing, progress towards
prevention and control is slow.  Sustained progress will
occur only when governments, international agencies,
NGOs and civil society acknowledge that the scope of
public health activities must be rapidly broadened to
include chronic diseases and their risk factors.  Chronic
disease prevention and control advocates should use
the MDG framework and experience as a model for
their own efforts, which should be synergistic with, but
not in competition with, the infectious disease agenda. 
Finally, most of the facts in this paper are known to
many policy makers and politicians. Yet action is
limited.  There is a serious need for research into the
most effective levers for policy change around the
chronic disease agenda.  With this knowledge we could
identify the best advocacy approaches and the best
entry points and partners for the multisectoral actions
that are required. Will childhood obesity, for example,
provide the spur for action?  It is often said that chronic
diseases began to be taken seriously in wealthy
countries as a response to their direct impact on
politicians.  Will we have to wait for a generation of
middle-aged politicians in low- and middle-income
countries to be struck down by heart attacks and
strokes before these issues are taken seriously?  The
fact that the WHO and many of its partners are now
taking chronic diseases more seriously provides hope
that we may be able to shortcut this process.
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Innovative solutions to nutritional
issues in Asia
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Asian countries are big, medium and small in size, and
comprise industrialised and developing countries.1
Some are in transitional states, reflected in their types
of nutritional problems. Industrialised countries are
more prone to overnutrition and related diseases, such
as obesity, high blood pressure, coronary heart disease,
cancer, etc., whereas the majority of nutritional
problems in developing countries are malnutrition, such
as protein energy malnutrition (PEM), and
micronutrient deficiencies especially iron deficiency
anaemia, and iodine and vitamin A deficiencies.1-4
Furthermore, vitamin B1, B2, B6, and folic acid
deficiencies cannot be discounted.1,5-10 Some transitional
countries are also facing increasing rates of overweight
and obesity, which can lead to degenerative diseases
such as diabetes mellitus, hypertension, coronary heart
disease and some types of cancer.11,12
Food-borne parasitic infections, some of which are very
dangerous, are also important problems affecting
health, such as liver fluke infection (Opisthorchis
viverrini), which can associate with some carcinogens,
e.g. N-nitroso compounds, and cause
cholangiocarcinoma (cancer of the bile canals).13,14 Food-
borne diseases caused by bacteria and viruses are also
of public health importance, especially diarrhoea.
Chemical toxins, such as aflatoxins caused by mould
growth (Aspergillus flavus), are also prevalent in the
tropics, since the temperature and humidity are
suitable for mould growth in agricultural products that
are inappropriately stored after harvest, especially
peanuts and corn. 8,9-epoxide, the metabolite product
of aflatoxin B1, is the ultimate carcinogen, which can
cause liver cancer.15 The other common carcinogens are
exogenous nitrosamines formed in cured meats, and/or
endogenous nitrosamines, which can be formed in the
stomach and small intestine.16 These various factors
highlight the very important issue of food safety, not
only at the household level, but also at national and
international levels, which can affect food exports. Food
contaminant limits should meet international
standards, e.g. the World Trade Organization (WTO),
CODEX Alimentarius. Diarrhoea caused by unsafe
foods can retard the growth of children, especially
infants and preschool children, and result in wasting
and stunting conditions.17
There are many other reasons for malnutrition, the
majority of which are poverty, production and
distribution of foods, lack of nutritional knowledge, and
ignorance. Many means of nutrition intervention can be
utilised, which should be appropriate and applicable to
the place and size of the problem(s).1,18 Successful pilot
projects have been implemented nationwide; however,
national implementation programmes cannot succeed
without the advocacy of policymakers, politicians,
academia, communities, and the general population.
Many projects should start from grassroots level,
signifying genuine popular participation, and the
utilisation of local resources and traditional knowledge
should be emphasised. In addition, modern
technologies should be transferred to communities.
International organisations are beneficial aids to
enlarging functional outcomes.19 With globalisation,
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